Applied Clinical Trials
Industry news focusing on the people and organizations who work in the clinical trials profession.
Graham Belgrave• As an active member of ICR (Bourne End, UK) for more than 20 years and a clinical research consultant for Ipsen Ltd (Slough, UK), Graham Belgrave has been recognized as the 100th ICR Chartered Scientist.
Megan Sturm
• Praxis (Nashville, TN) has added Megan Sturm to its staff as the new business development manager, where she will oversee the company's activities in its Northeast United States and Southern California areas.
Emma Clayton
• With more than 10 years of conference and exhibition management experience, Emma Clayton has become ICR's (Bourne End, UK) new conference project manager.
• Covance (Princeton, NJ) has made several executive appointments, including Glynis Neagle, MD, as vice president for medical affairs; Robert Bader, PharmD, as director for product safety services; and Thomas Noto as vice president for regulatory affairs.
Glynis Neagle
• Richard Walovitch is WorldCare's (Boston, MA) new chief medical officer. He will bring with him over 20 years of management experience in preclinical and clinical development for therapeutics and diagnostics.
• Hans-Georg Eichler, MD, senior medical officer for the EMEA, has become the first non-U.S. regulatory liaison to the Clinical Trials Transformation Initiative Executive Committee. Dr. Eichler will fill the recently created nonvoting position.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Full Phase IIIb BATURA Trial Results Show Airsupra Cuts Severe Exacerbations by 47% in Mild Asthma
May 20th 2025Results from the pivotal BATURA trial show that Airsupra (albuterol/budesonide) significantly outperformed albuterol monotherapy in reducing severe asthma exacerbations and systemic corticosteroid exposure, reinforcing its role as a next-generation, anti-inflammatory rescue therapy for mild asthma patients.